Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ODC1 | P11926 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL667646 | 1.00 | — | — | |
| SCHEMBL11885390 | 1.00 | ODC1 (0.41) | ODC1ADRB2ADRB1ADRB3MEN1 | |
| SCHEMBL758346 | 1.00 | ODC1 (0.41) | ODC1ADRB2ADRB1ADRB3MEN1 | |
| SCHEMBL10076924 | 1.00 | ODC1 (0.41) | ODC1ADRB2ADRB1ADRB3MEN1 | |
| Water SCHEMBL20496293 | 0.96 | ODC1 (0.39) | ODC1ADRB2ADRB1ADRB3MEN1 | |
| SCHEMBL22169531 | 0.89 | ODC1 (0.42) | ODC1ADRB2ADRB1ADRB3MEN1 | |
| SCHEMBL24500071 | 0.86 | ODC1 (0.47) | ODC1ADRB2ADRB1ADRB3MEN1 | |
| SCHEMBL16329755 | 0.86 | ODC1 (0.47) | ODC1ADRB2ADRB1ADRB3MEN1 | |
| SCHEMBL13221671 | 0.86 | ODC1 (0.47) | ODC1ADRB2ADRB1ADRB3MEN1 | |
| SCHEMBL2127510 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160355859-A1 | TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES | NOVO NORDISK A/S (DK) | 2016-12-08 | — | — | US | claimed |
| US-9505900-B2 | Method for producing xerogel composites | BASF SE (DE) | 2016-11-29 | — | — | US | claimed |
| CN-103215328-A | Transglutaminase mediated conjugation of peptides | NOVO NORDISK AS | 2013-07-24 | — | — | CN | claimed |
| EP-2033662-B1 | Transglutaminase mediated conjugation of peptides | NOVO NORDISK HEALTHCARE AG (CH) | 2012-10-17 | — | — | EP | claimed |
| EP-2368579-A1 | Transglutaminase mediated conjugation of peptides | Novo Nordisk Health Care AG (CH) | 2011-09-28 | — | — | EP | claimed |
| US-20100009917-A1 | Modulating Enzymatic Processes by Addition of Diolcontaining Substances | NOVO NORDISK HEALTH CARE AG (CH) | 2010-01-14 | — | — | US | claimed |
| US-20090264366-A1 | Transglutaminase Mediated Conjugation of Peptides | NOVO NORDISK HEALTHCARE AG (CH) | 2009-10-22 | — | — | US | claimed |
| EP-2033662-A1 | Transglutaminase mediated conjugation of peptides | Novo Nordisk Health Care AG (CH) | 2009-03-11 | — | — | EP | claimed |
| US-20070105770-A1 | Transglutaminase mediated conjugation of peptides | NOVO NORDISK A/S (DK) | 2007-05-10 | — | — | US | claimed |
| EP-3838927-B1 | CROSS-LINKED HYALURONIC ACID AND USE THEREOF FOR LIMITING THE RECURRENCE OF A TUMOUR | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2024-10-09 | — | — | EP | disclosed |
| US-20230364262-A1 | VIA CYCLOADDITION BILATERALLY FUNCTIONALIZED ANTIBODIES | SYNAFFIX B.V. (NL) | 2023-11-16 | — | — | US | disclosed |
| US-20230190951-A1 | CONJUGATES OF ANTIBODIES AN IMMUNE CELL ENGAGERS | SYNAFFIX B.V. (NL) | 2023-06-22 | — | — | US | disclosed |
| US-20230114866-A1 | VIA CYCLOADDITION BILATERALLY FUNCTIONALIZED ANTIBODIES | SYNAFFIX B.V. (NL) | 2023-04-13 | — | — | US | disclosed |
| WO-2021144313-A1 | VIA CYCLOADDITION BILATERALLY FUNCTIONALIZED ANTIBODIES | SYNAFFIX B.V. (NL) | 2021-07-22 | — | — | WO | disclosed |
| EP-1183230-A1 | VALENCY PLATFORM MOLECULES COMPRISING AMINOOXY GROUPS | LA JOLLA PHARMACEUTICAL (US) | 2002-03-06 | — | — | EP | disclosed |
| EP-1092027-A1 | THERAPEUTIC AND DIAGNOSTIC DOMAIN 1 BETA 2 GP1 POLYPEPTIDES AND METHODS OF USING SAME | LA JOLLA PHARMACEUTICAL COMPANY (CA) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000075105-A1 | VALENCY PLATFORM MOLECULES COMPRISING AMINOOXY GROUPS | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2000-12-14 | — | — | WO | disclosed |
| WO-1999064595-A9 | THERAPEUTIC AND DIAGNOSTIC DOMAIN 1 β2GPI POLYPEPTIDES AND METHODS OF USING SAME | JOLLA PHARMA (US) | 2000-09-08 | — | — | WO | disclosed |
| WO-1999064595-A1 | THERAPEUTIC AND DIAGNOSTIC DOMAIN 1 β2GPI POLYPEPTIDES AND METHODS OF USING SAME | LA JOLLA PHARMACEUTICAL COMPANY (US) | 1999-12-16 | — | — | WO | disclosed |
| US-4714750-A | Synthesis of products from polyoxyalkylene amines and 2,6-di-t-butylphenol for use as epoxy accelerators and curing agents | TEXACO INC. (US) | 1987-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230114866-A1 | VIA CYCLOADDITION BILATERALLY FUNCTIONALIZED ANTIBODIES | FUT5, FUCA1, FUT6 | ODC1 2187/4885ADRB2 1301/4885ADRB1 1062/4885 |
| US-20090264366-A1 | Transglutaminase Mediated Conjugation of Peptides | TGM2, TGM3, TGM1 | ODC1 412/4885ADRB2 4834/4885ADRB1 4813/4885 |
| US-20100009917-A1 | Modulating Enzymatic Processes by Addition of Diolcontaining Substances | HSD17B14, CES2, PNLIP | ODC1 361/4885ADRB2 2061/4885ADRB1 1823/4885 |
| US-20070105770-A1 | Transglutaminase mediated conjugation of peptides | TGM2, TGM3, TGM1 | ODC1 412/4885ADRB2 4834/4885ADRB1 4813/4885 |
| US-20230190951-A1 | CONJUGATES OF ANTIBODIES AN IMMUNE CELL ENGAGERS | FCGR3B, FCGR1A, FCGR2A | ODC1 4712/4885ADRB2 4829/4885ADRB1 4542/4885 |
| US-20230364262-A1 | VIA CYCLOADDITION BILATERALLY FUNCTIONALIZED ANTIBODIES | FCGR1A, FCGR3B, FCGR2A | ODC1 2301/4885ADRB2 767/4885ADRB1 515/4885 |
| US-20160355859-A1 | TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES | TGM2, TGM3, TGM1 | ODC1 412/4885ADRB2 4834/4885ADRB1 4813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.